Skip to content

Randomized Controlled Study of Modified Cangfu Daotan Granule in the Treatment of Infertility with Overweight Polycystic Ovary Syndrome

Randomized Controlled Study of Modified Cangfu Daotan Granule in the Treatment of Infertility with Overweight Polycystic Ovary Syndrome

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100053290
Enrollment
Unknown
Registered
2021-11-18
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility with Overweight Polycystic Ovary Syndrome

Interventions

Experimental group:Western Medicine and Modified Cangfu Daotan Granule
Control group:Western Medicine and placebo granule

Sponsors

Maternal and Child Health Hospital of Hubei Province
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic criteria of overweight, PCOS and infertility, as well as the TCM syndrome differentiation criteria of kidney deficiency and phlegm dampness syndrome; 2. Female aged 20-40 years; 3. Willing to receive treatment and voluntarily sign informed consent; 4. There were no organic lesions in the reproductive system; 5. Bilateral fallopian tubes were unobstructed by radiography; 6. Immune infertility antibodies were normal.

Exclusion criteria

Exclusion criteria: 1. Complicated with serious primary diseases such as cardiovascular, liver, kidney and hematopoietic system; 2. High gonadotropins such as premature ovarian failure and ovarian insensitivity syndrome; 3. Adrenal glands, thyroid, diabetes and other endocrine glands were abnormal; 4. Male infertility factors; 5. Psychiatric patients; 6. Allergic constitution or allergic to the study drug; 7. Patients with metformin contraindications; 8. Patients with contraindications or cautious use of short acting compound oral contraceptives (COC); 9. Failure to use drugs according to regulations, inability to judge the curative effect or incomplete data affect the judgment of curative effect.

Design outcomes

Primary

MeasureTime frame
Continuous pregnancy rate;

Secondary

MeasureTime frame
Body mass index;TCM syndrome score;Sex hormone;Homeostatic model assessment of insulin resistance;Effective rate;Cure rate;Cycle ovulation rate;Pregnancy rate;Clinical pregnancy rate;Early pregnancy loss rate;

Countries

China

Contacts

Public ContactHe Danjuan

Maternal and Child Health Hospital of Hubei Province

danjuanhe@163.com+86 18062414840

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026